Palmoplantar pustulosis (PPP) is clinically significant due to its impact on the quality of life of affected individuals. This chronic skin condition, characterized by sterile pustules on the palms and soles, can cause pain, discomfort, and functional impairment, particularly in activities that involve the use of hands and feet. Beyond the physical symptoms, PPP often carries psychosocial consequences, contributing to emotional distress and decreased self-esteem. Given its chronic nature, PPP necessitates ongoing management, and effective treatment options are crucial for alleviating symptoms and improving the overall well-being of patients.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/japan-palmoplantar-pustulosis-ppp-market
Data Bridge Market Research analyses that the Japan Palmoplantar Pustulosis (PPP) Market is expected to grow at a CAGR of 6.3% in the forecast period of 2023 to 2030 and the market is valued at USD 135.9 million in 2022, and it will grow to USD 221.6 million by 2030. The diverse range of treatment options for palmoplantar pustulosis (PPP), such as light therapy, retinoids, and biologics such as adalimumab, brodalumab, and certolizumab pegol, enhances the chances of finding effective solutions for individual patients. The availability of multiple treatment modalities contributes to increased market demand and potential growth.
Key Findings of the Study
Increasing awareness about PPP leads to early diagnosis is expected to drive the market's growth rate
The increasing awareness of palmoplantar pustulosis (PPP) among both patients and healthcare professionals presents a significant market opportunity. As more cases are diagnosed due to heightened awareness through patient advocacy groups and educational campaigns, the demand for effective PPP treatments is expected to rise. This creates a favorable environment for pharmaceutical companies to develop and market innovative therapies to address the growing needs of individuals affected by PPP.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Type (Diagnosis and Treatment), Population Type (Children and Adults), Route of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Amgen inc. (U.S.), AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Japan palmoplantar pustulosis (PPP) market is segmented on the basis of
disease type, severity, type, population type, route of administration, end-users, and distribution channel.
- On the basis of disease type, the Japan palmoplantar pustulosis (PPP) market is segmented into type A and type B
- On the basis of severity, the Japan palmoplantar pustulosis (PPP) market is segmented into mild-moderate and moderate-severe
- On the basis of type, the Japan palmoplantar pustulosis (PPP) market is segmented into diagnosis and treatment
- On the basis of population type, the Japan palmoplantar pustulosis (PPP) market is segmented into children and adults
- On the basis of route of administration, the Japan palmoplantar pustulosis (PPP) market is segmented into oral, topical and parenteral
- On the basis of end-users, the Japan palmoplantar pustulosis (PPP) market is segmented into hospitals, homecare, specialty clinics, and others
- On the basis of distribution channel, the Japan palmoplantar pustulosis (PPP) market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy
Major Players
Data Bridge Market Research recognizes the following companies as the major Japan palmoplantar pustulosis (PPP) market players in Japan palmoplantar pustulosis (PPP) market are Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.)
Market Developments
- In June 2022, Aristea Therapeutics Inc., a clinical-stage immunology company focused on innovative drug development for severe inflammatory diseases, announced the dosing of the first subject in the Open-Label Extension (OLE) for its Phase 2b trial of RIST4721 in Palmoplantar Pustulosis (PPP), a rare dermatological condition
- In July 2020, Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson Services, Inc., achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for STELARA (ustekinumab). This monoclonal antibody garnered approval for its efficacy in treating various inflammatory conditions, establishing its capability to suppress overactive inflammatory responses. This regulatory green light proved pivotal for Janssen Pharmaceuticals, as it opened the gateway for the commercialization of STELARA in the treatment of palmoplantar pustulosis. This specific indication addressed a medical need, further enhancing the drug's market potential.
- In October 2020, UCB, a global biopharmaceutical company, disclosed new data on bimekizumab, an investigational IL-17A and IL-17F inhibitor, and CIMZIA (certolizumab pegol), a TNF inhibitor, for the treatment of moderate-to-severe plaque psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam
- In February 2020, Eli Lilly and Company successfully acquired Dermira Inc., a prominent dermatology medicines developer. This strategic acquisition marked a significant expansion for Eli Lilly, strengthening its portfolio in the dermatology sector. The move allowed Eli Lilly to tap into Dermira's expertise and innovative pipeline of dermatological treatments, further enhancing its presence and capabilities in the pharmaceutical industry
For more detailed information about the Japan palmoplantar pustulosis (PPP) market report, click here – https://www.databridgemarketresearch.com/fr/reports/japan-palmoplantar-pustulosis-ppp-market
